Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
|Podcasts|March 11, 2022
Powder Handling Challenges in Upstream Biopharmaceutical Processes
Author(s)ILC Dover
For years pharmaceutical and biopharmaceutical manufacturers have invested in rigid stainless-steel equipment for upstream bioprocessing. With new and innovative single-use products now on the market, manufacturers have access to flexible, safe solutions that offer a myriad of advantages over the traditional solutions. Single-use technology offers less risk of contamination, more operator safety, and less negative environmental impact than the stainless-steel alternatives. In this podcast, we will discuss the challenges associated with handling powders in upstream biopharm processes and how single-use technology can benefit manufacturers from an environmental, cost, and safety perspective.
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.